Emergency Rule Related to Telemedicine

Posted in Latest News on May 6, 2014.

On March 12, 2014, Board of Medicine’s Rule 64B8-9.0141 went into effect wherein the Board set forth standards for telemedicine practice for Florida licensed physicians. Rule 64B8-9.0141(4) specifically precludes physicians from prescribing controlled substances through the use of telemedicine.

Shortly thereafter, the Board of Medicine began to receive reports from physicians and hospital representatives that expressed concern that the Board’s standards for telemedicine practice rule precludes physicians from ordering controlled substances through the use of telemedicine for their hospitalized patients. Rule 64B8-9.0141(4) precludes the prescribing of controlled substances through the use of telemedicine, but it was never the Board’s intent to preclude the use of telemedicine modalities to order controlled substances to hospitalized patients.

The aforementioned controlled substance prescribing prohibition has inadvertently created doubt amongst physicians about their ability to order controlled substances through the use of telemedicine for their hospitalized patients. This doubt likely arises from the lack of clear definition for the term “prescribing” as set forth Florida Statutes. Therefore, the Board of Medicine has filed a narrowly tailored emergency rule amending Rule 64B8-9.0141 to clarify that the ordering of controlled substances for hospitalized patients through the use of telemedicine is not precluded by Rule 64B8-9.0141(4).

This emergency, which goes into effect on April 30, 2014, is designed to prevent patient harm, does not harm licensees or any health care practitioners in any way, and most importantly clarifies the limited scope Rule 64B8-9.0141(4).



More Latest News

Bills That Go Into Effect January 1, 2017
February 17, 2017

SB 0422 Relating to Health Insurance Coverage For Opioids Health Insurance Coverage For Opioids; Providing that a health insurance policy that covers abuse-deterrent opioid analgesic drug products may impose a prior authorization requirement for an abuse-deterrent opioid analgesic drug product … Continue reading


DEA’s suspension of McKesson Corporation Retraction
January 19, 2017

Please see updated information about the DEA’s suspension of McKesson Corporation and controlled substances Continue reading